🩷 This #BreastCancerAwarenessMonth, and every month, we stand with patients, families, caregivers, and healthcare professionals. At Alterome, we’re advancing precision medicines that aim to bring more time, options, and hope to those facing breast cancer. #OncSky

Precision, execution, and experience are just a few of the attributes that make Alterome fierce. We would like to thank our team, who embody these attributes every day, for our recognition as one of the fiercest biotechs of 2025. Read more: www.fiercebiotech.com/special-repo...

#OncSky #Cansky

We are proud to be named one of the Best Places to Work by the San Diego Business Journal for the third year in a row! Grateful to our amazing team whose passion for advancing cancer therapies makes Alterome such a special place. #OncSky

To kick off back-to-school season in #SanDiego, #TeamAlterome joined @lifesciencecares.bsky.social‬ & @hopethroughhousing.bsky.social‬ for a backpack build to support students & families in our community. #Scisky #Oncsky

#TeamAlterome joined the #Curebound Cancer Challenge — helping raise $3.3M for cancer research at leading #SanDiego research institutions. We are proud to walk, run, and ride with our community that is working to end cancer as we know it. #OncSky

#TeamAlterome is grateful for the San Diego community that consistently supports our team. As part of our commitment to giving back, earlier this month we participated in a beach clean-up, removing nearly 200 pounds of trash cluttering La Jolla Shores Beach. #OncSky

June is National Cancer Survivorship Month—a time to honor the strength of those living with cancer and focus on enhancing the quality and length of survival of all persons diagnosed with cancer. Alterome is committed to that mission this month and every month. #OncSky

#TeamAlterome is fresh off our time at #ASCO25 (@ascocancer.bsky.social)! We valued the time spent connecting with other leaders in #CancerResearch and discussing our two precision oncology clinical programs focused on #AKT and #KRAS. #OncSky

14,000 US patients with HR+ breast cancer are affected by the AKT1 E17K mutation. This mutation also affects ~2% of all cancers, including endometrial and prostate. Alterome’s ALTA2618 is the first drug in the clinic specially designed to meet the needs of these patients. #OncSky

Today on #ClinicalTrialsDay, we honor the patients, caregivers, HCPs, & clinical research teams progressing cutting edge cancer programs, like ALTA2618 & ALTA3263. At Alterome, we are “Powered by Purpose” to develop precise therapies for #AKT & #KRAS-driven cancers.

May is #NationalCancerResearchMonth. At Alterome, we’re developing small molecule therapies that precisely target elusive cancer drivers where patients have few treatment options. Hear from Xuefeng Zhu, VP of Medicinal Chemistry, on what fuels his drive to innovate.

Alterome runs smoothly thanks to Patty Quintana & Cailin Fredrickson! Their dedication and organization keep our team on track every day. We are grateful for all that you do! #TeamAlterome #AdministrativeProfessionalsDay

#KRAS mutations drive >20% of cancers. Once “undruggable,” first-gen inhibitors proved KRAS could be targeted. ALTA3263 is a next-gen, isoform-selective therapy with ON/OFF-state inhibition, designed to overcome first-gen limitations. Learn more: bit.ly/3EAqHIq
#Oncology

The first patient has been dosed in our Phase 1/1b trial of ALTA3263, a KRAS selective (ON/OFF) inhibitor, for KRAS-mutant solid tumors. This is a key step toward our mission to transform the lives of cancer patients, one alteration at a time. Read more: bwnews.pr/4ixQBve

We heard it’s time to alter our approach. Hi, Bluesky! We’re developing next-gen precision oncology therapies for patients who have very few treatment options. Re-share so we can connect and grow the biotech & oncology community here together! 🔬🌱